Three FDA Approvals in Three Months Transform Hereditary Angioedema Treatment Landscape in 2025
核心洞察
The FDA approved three new hereditary angioedema (搜索) treatments in just three months during 2025: CSL (搜索)'s Andembry in June, KalVista's Ekterly in July, and Ionis's Dawnzera in August.
These approvals represent breakthrough innovations including the first factor XIIa (搜索) inhibitor, first oral on-demand therapy, and first RNA-targeting treatment for HAE (搜索) prevention.
The rapid succession of approvals brings the total number of FDA-approved HAE (搜索) treatments from 9 to 12, offering unprecedented treatment options for the estimated 7,000 U.S. patients.
The hereditary angioedema (搜索) (HAE (搜索)) treatment landscape underwent a dramatic transformation in 2025, with the FDA approving three novel therapies in rapid succession over just three months. This unprecedented regulatory activity has expanded treatment options for patients with the rare genetic condition that affects approximately 7,000 people in the United States.
Trio of Breakthrough Approvals
The regulatory momentum began in June with CSL (搜索)'s approval of garadacimab-gxii (搜索) (Andembry), the first factor XIIa (搜索) inhibitor for HAE (搜索) prophylaxis. KalVista Pharmaceuticals followed in July with sebetralstat (Ekterly), marking the first oral on-demand therapy for acute HAE attacks. Ionis Pharmaceuticals (搜索) completed the trilogy in August with donidalorsen (Dawnzera), the first RNA-targeting therapy for HAE prevention.
"It's awesome. I love them all. It's like my children; you don't have a favorite," said Daniel Soteres, MD, PhD, from the University of Colorado Health Sciences Center. "Every patient has an individual set of values, an individual health literacy. Their needs change over time. Having multiple options available for these patients is important."
Clinical Efficacy and Novel Mechanisms
Each approved therapy demonstrated compelling clinical results through distinct mechanisms of action. Garadacimab-gxii (搜索) targets the top of the HAE (搜索) cascade, achieving 62% of patients remaining attack-free with ≥99% reductions in overall HAE attacks compared to placebo in the pivotal VANGUARD trial. The therapy offers once-monthly dosing from day one, administered through a citrate-free autoinjector in 15 seconds or less.
Sebetralstat, a plasma kallikrein (搜索) inhibitor, showed rapid symptom relief in the KONFIDENT trials, with a median time to symptom relief of 1.3 hours across 136 patients. Among 19 adolescent patients, the median time from attack onset to treatment was just 4 minutes, with complete resolution occurring by 15.09 hours.
Donidalorsen demonstrated sustained attack reduction by targeting prekallikrein (搜索) production. In the OASIS-HAE (搜索) trial, the 80 mg dose administered every 4 weeks reduced monthly attack rates by 81%, with 91% of patients achieving good disease control. Long-term data from the ongoing phase 2 OLE study showed a 96% mean reduction in attacks over 3 years.
Market Dynamics and Patient Adoption
The HAE (搜索) market, projected to reach nearly $6 billion by 2030 according to Grand View Research, presents both opportunities and challenges for new entrants. Takeda (搜索)'s Takhzyro currently dominates with approximately $1.7 billion in annual sales, having surpassed earlier treatments since its 2018 approval.
However, patient adoption patterns may limit rapid uptake of new therapies. "Patients are often 'sticky' with their existing treatments and often view switching treatments as an unnecessary risk if their current therapies are working," noted Myles Minter, biotech equity research analyst at William Blair.
Despite this market dynamic, an Ionis-sponsored survey revealed that 9 of 10 HAE (搜索) patients expressed interest in trying new prophylactic therapy, with nearly two-thirds reporting they hadn't found the best treatment option. "In the U.S., many people living with HAE remain unsatisfied with their current treatment, continuing to experience painful, unpredictable attacks," said Kyle Jenne, chief global product strategy officer at Ionis.
Addressing Unmet Medical Needs
The therapeutic advances come at a critical time for HAE (搜索) patients, who face significant disease burden throughout their lives. Recent data presented at the 2025 American College of Allergy, Asthma & Immunology conference showed that children with HAE often experience delayed or inconsistent emergency care, with studies revealing greater academic impact than previously recognized.
The disease's severity is underscored by diagnostic challenges, with up to 90% of HAE (搜索)-related deaths occurring in undiagnosed patients experiencing asphyxiation, according to a May 2025 report.
Pipeline Developments and Future Directions
Beyond the recent approvals, several promising candidates remain in development. Intellia Therapeutics' lonvoguran ziclumeran (搜索) (NTLA-2002), a CRISPR-based gene therapy, showed that 97% of patients receiving a 50-mg dose were attack-free and long-term prophylaxis-free as of the August 29 data cutoff, with patients followed for up to 32 months.
Other pipeline candidates include ADARx Pharmaceuticals (搜索)' ADX-324, a short-interfering RNA therapy; Pharvaris' deucrictibant, an oral bradykinin B2 receptor (搜索) antagonist; and Astria (搜索)'s navenibart, a subcutaneous plasma kallikrein (搜索) inhibitor.
Pediatric Treatment Gap
Despite the therapeutic progress, experts identified a critical unmet need for treatments indicated in children under 12 years old. "HAE (搜索) is really a disease of childhood," said Michael Manning, MD, an allergy, asthma, & immunology specialist. "Eighty-five percent of patients develop symptoms before the age of 20."
Soteres emphasized the urgency of addressing pediatric needs: "The attacks actually start a lot younger, as early as 5 years old, and some reports even as young as 2. As a pediatric-trained hereditary angioedema (搜索) specialist, I see a lot of adults, but I do worry about the younger ones."
The rapid succession of HAE (搜索) approvals reflects unprecedented momentum in rare disease drug development. "We joke a little bit that there's going to be more HAE drugs than patients out there," Manning noted. "The more we know, and the better we get at treating this, the better we get [at] finding a medication that is going to reach that goal of total control."